Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumour-directed immuno-oncology antibody drugs, announced on Friday that it has named Dr Malin Carlsson as its new chief operating officer, effective 1 January 2020.
Dr Carlsson most recently held the position of vice president, head of Translational Medicine at Ferring Pharmaceuticals in Copenhagen. She is a medical doctor with specialist qualifications and a PhD in clinical immunology. She also has many years of industrial experience from various senior roles in major international pharmaceutical companies such as AstraZeneca, Nycomed, Takeda and Ferring.
Per Norlén, Alligator Bioscience CEO, said, 'I am very pleased with the successful recruitment of Malin Carlsson to Alligator. Her international experience in leading clinical development and in building development organisations will significantly strengthen our clinical capacity. This is crucial in the phase we are in now, with two products on the way to phase II and another product in clinical phase I. We look forward to welcoming Malin to Lund and to our management team.'
Aptagen awarded contract for developing parasitic disease diagnostic
Wave Neuroscience acquires brain treatment technology assets from NBRL
US FDA grants breakthrough therapy status to Bristol-Myers Squibb's Orencia
Gatehouse Bio forms collaboration with AstraZeneca
Alzheimer's, Parkinson's Collaboration of Mission and AbbVie Reaches Milestone
FDA Advisory Committee Will Review Reblozyl for Use in Patients with Myelodysplastic Syndromes